My pick for the best 50-inch TV is the Samsung QN90D for its updated Neo QLED panel, Dolby Atmos support and object tracking sound, dedicated gaming hub with access to cloud gaming services ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression ... using one antidepressant medication, and 50% have no response with just one drug.

As the champion all-rounder prepares for the first women’s Test match at the MCG in 75 years, and the first day-night Test ever at the iconic ground, starting against England next Thursday ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Being a 50-something is tricky. Midlife crises may be largely complete, greying hair and ageing ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in ...

it won’t work if you have severe inflammation in your nose blocking the nasal passages. Smith suggests using a decongestant spray for no more than three days in a row to help shrink the swelling down, ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

That’s where the best hairstyles for women over 50 come into play. “As women age, [we] tend to run into thinning hair, and loss of elasticity and shine,” says Carrie Butterworth, a freelance ...

Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...